Learn Before
Relation
28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project
DEX usage reduced 28-day mortality for patients requiring mechanical ventilation and, to a lesser degree, patients receiving other oxygen therapy.
- Methods
- Results
- Discussion
0
1
Updated 2026-07-04
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Learn After
Methods : 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project
Results : 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project